Shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) have received an average recommendation of “Hold” from the nineteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $50.33.
XRAY has been the topic of a number of analyst reports. Goldman Sachs Group upgraded DENTSPLY SIRONA from a “sell” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Friday, October 19th. Barrington Research restated a “hold” rating on shares of DENTSPLY SIRONA in a research report on Friday, November 9th. UBS Group initiated coverage on DENTSPLY SIRONA in a research report on Thursday, January 17th. They set a “neutral” rating and a $42.00 target price on the stock. ValuEngine upgraded DENTSPLY SIRONA from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 24th. Finally, BidaskClub upgraded DENTSPLY SIRONA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 12th.
In related news, insider Markus Boehringer sold 7,373 shares of DENTSPLY SIRONA stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $37.86, for a total value of $279,141.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.93% of the company’s stock.
A number of hedge funds have recently bought and sold shares of XRAY. QUANTRES ASSET MANAGEMENT Ltd purchased a new position in DENTSPLY SIRONA in the 3rd quarter worth approximately $577,000. Bank of Montreal Can lifted its stake in DENTSPLY SIRONA by 65.8% in the 3rd quarter. Bank of Montreal Can now owns 388,396 shares of the medical instruments supplier’s stock worth $14,658,000 after purchasing an additional 154,125 shares in the last quarter. Advisor Partners LLC purchased a new position in DENTSPLY SIRONA in the 4th quarter worth approximately $367,000. NuWave Investment Management LLC lifted its stake in DENTSPLY SIRONA by 22,360.0% in the 3rd quarter. NuWave Investment Management LLC now owns 3,369 shares of the medical instruments supplier’s stock worth $127,000 after purchasing an additional 3,354 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in DENTSPLY SIRONA by 459.2% in the 3rd quarter. SG Americas Securities LLC now owns 116,189 shares of the medical instruments supplier’s stock worth $4,385,000 after purchasing an additional 95,413 shares in the last quarter. Institutional investors own 97.09% of the company’s stock.
NASDAQ:XRAY opened at $43.87 on Thursday. DENTSPLY SIRONA has a 52 week low of $33.93 and a 52 week high of $59.17. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.76. The stock has a market cap of $9.48 billion, a PE ratio of 16.49, a price-to-earnings-growth ratio of 2.36 and a beta of 1.06.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Recommended Story: Buyback For Investors Defined
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.